Eli Lilly in Talks to Acquire Kelonia Therapeutics for Over $2 Billion 
Jeff Bezos Eyes $10 Billion Funding Round for AI Venture Project Prometheus 
Apple Wins ITC Ruling, Keeping Blood-Oxygen Feature on Apple Watch 
John Ternus Signals Apple’s Future with Product-First AI Strategy 
OPmobility Reports Q1 Revenue Dip Amid Automotive Industry Slowdown 
Australia Extends Fuel Sulphur Relaxation Amid Iran War Supply Disruptions 
OpenAI's $20 Billion Cerebras Deal Signals Massive AI Infrastructure Push 
Apple Stock Dips as Tim Cook Steps Down, John Ternus Named Next CEO 
Indonesia and Toyota Explore $300M Bioethanol Investment to Boost Renewable Energy Goals 
J.P. Morgan Downgrades Essity AB on Rising Costs and Weak Earnings Outlook 
Anthropic CEO Meets Trump Officials to Discuss Powerful New AI Model Mythos 
SK Hynix Launches 192GB SOCAMM2 Memory for Nvidia’s Next-Gen AI Chips 
Elon Musk Faces French Probe Over X and Grok Amid Rising U.S.-EU Tensions 
Ethiopian Airlines Expands Fleet with New Boeing 787 Dreamliner Order to Boost Global Routes 
SpaceX President Gwynne Shotwell Earns $85.8M as IPO Buzz Grows 
JAPEX Shares Drop as Middle East Tensions Drive LNG Costs and Production Risks 
Polymarket Seeks $400M Funding Round, Targets $15B Valuation Amid Prediction Market Boom 
REHOVOT, Israel, May 30, 2017 -- NeuroDerm Ltd. (Nasdaq:NDRM), a clinical stage pharmaceutical company developing drug-device combinations for central nervous system (CNS) disorders, today announced that CEO Oded S. Lieberman, PhD will present at the Jefferies Global Healthcare Conference on Wednesday, June 7 at 2:30 pm ET in New York. Dr. Lieberman will give a corporate overview and discuss the company's flagship product candidates designed to treat moderate to severe Parkinson's disease.
To access the live webcast of the presentation, please visit ir.neuroderm.com/. A replay will be available for a limited time following the presentation.
About NeuroDerm
NeuroDerm is a clinical-stage pharmaceutical company developing central nervous system (CNS) product candidates that are designed to overcome major deficiencies of current treatments and achieve enhanced clinical efficacy through continuous, controlled administration. NeuroDerm’s main focus is in Parkinson's disease, where it has three clinical stage product candidates in development which offer a solution for almost every Parkinson’s disease patient, from moderate to the very severe stage of the disease. The primary product candidates are a line of levodopa and carbidopa (LD/CD) products administered through small belt pumps that deliver a continuous, controlled dose of LD/CD. The LD/CD product candidates, ND0612L and ND0612H, are aimed at the treatment of moderate and advanced Parkinson’s disease patients, respectively, and are delivered subcutaneously. NeuroDerm is also designing a patch pump for future use. In addition, NeuroDerm is developing ND0701, a novel subcutaneously delivered apomorphine formulation for patients who suffer from moderate to severe Parkinson’s disease and who do not respond well to LD/CD. NeuroDerm is headquartered in the Weizmann Science Park in Rehovot, Israel.
NeuroDerm Contact:
Oded S. Lieberman, PhD, CEO
[email protected]
Tel.: +972-8-946 2729
Cell: +1-617-517 6077
U.S. Investor Contact:
David Carey
Lazar Partners Ltd.
[email protected]
+212-867-1768
